Teladoc Inc (NYSE:TDOC) – Investment analysts at William Blair decreased their FY2017 earnings per share estimates for shares of Teladoc in a research note issued to investors on Tuesday. William Blair analyst R. Daniels now expects that the health services provider will earn ($1.55) per share for the year, down from their prior estimate of ($1.54). William Blair also issued estimates for Teladoc’s Q4 2017 earnings at ($0.41) EPS, Q1 2018 earnings at ($0.48) EPS, Q2 2018 earnings at ($0.34) EPS, Q3 2018 earnings at ($0.32) EPS, Q4 2018 earnings at ($0.27) EPS, FY2018 earnings at ($1.40) EPS and FY2019 earnings at ($0.81) EPS.

Teladoc (NYSE:TDOC) last released its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.25). Teladoc had a negative return on equity of 29.70% and a negative net margin of 45.64%. The business had revenue of $68.70 million during the quarter, compared to the consensus estimate of $67.53 million. During the same period in the previous year, the company posted ($0.33) EPS. The company’s revenue for the quarter was up 112.0% compared to the same quarter last year.

Several other research analysts have also recently issued reports on the company. KeyCorp reissued a “buy” rating and issued a $41.00 price target on shares of Teladoc in a research note on Wednesday. Citigroup began coverage on Teladoc in a research note on Thursday, January 4th. They issued a “buy” rating for the company. ValuEngine raised Teladoc from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Deutsche Bank started coverage on Teladoc in a research note on Friday, December 8th. They issued a “buy” rating and a $39.00 price target for the company. Finally, CIBC reaffirmed an “outperform” rating and set a $45.00 target price (up previously from $40.00) on shares of Teladoc in a research note on Tuesday, November 21st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $39.31.

Teladoc (NYSE TDOC) opened at $32.65 on Friday. Teladoc has a 52 week low of $15.65 and a 52 week high of $38.40. The stock has a market capitalization of $1,980.00 and a price-to-earnings ratio of -22.52. The company has a quick ratio of 5.08, a current ratio of 5.08 and a debt-to-equity ratio of 0.83.

In related news, CEO Jason N. Gorevic sold 20,000 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $32.10, for a total transaction of $642,000.00. Following the completion of the transaction, the chief executive officer now owns 838,261 shares of the company’s stock, valued at $26,908,178.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Jason N. Gorevic sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $32.99, for a total value of $3,299,000.00. Following the transaction, the chief executive officer now directly owns 718,261 shares of the company’s stock, valued at approximately $23,695,430.39. The disclosure for this sale can be found here. Insiders have sold 210,000 shares of company stock valued at $6,889,350 in the last ninety days. Company insiders own 4.47% of the company’s stock.

Several large investors have recently added to or reduced their stakes in TDOC. ETF Managers Group LLC acquired a new position in shares of Teladoc in the 2nd quarter valued at $104,000. Pacad Investment Ltd. acquired a new position in shares of Teladoc in the 2nd quarter valued at $135,000. Fred Alger Management Inc. acquired a new position in shares of Teladoc in the 2nd quarter valued at $139,000. Ameritas Investment Partners Inc. boosted its position in shares of Teladoc by 134.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after purchasing an additional 2,707 shares during the period. Finally, Oppenheimer Asset Management Inc. acquired a new position in shares of Teladoc in the 2nd quarter valued at $166,000.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/william-blair-comments-on-teladoc-incs-fy2017-earnings-tdoc/1805125.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Earnings History and Estimates for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with Analyst Ratings Network's FREE daily email newsletter.